NASDAQ$TSHA
Taysha Gene Therapies Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Taysha Gene Therapies reported financial results for the second quarter and provided a corporate update.
Taysha Gene Therapies reported a net loss of $40.9 million for the second quarter ended June 30, 2021. The company had $197.4 million in cash and cash equivalents as of June 30, 2021. They also secured a non-dilutive term loan for up to $100 million.
- Positive pre-IND/CTA feedback was obtained from regulatory agencies for Rett syndrome, GM2 gangliosidosis and CLN1 disease programs.
- A non-dilutive term loan agreement was entered into with Silicon Valley Bank for up to $100 million.
- Multiple successful GMP runs provided drug products to support five planned Phase 1/2 trials.
- Phase 1/2 visual acuity data for TSHA-120 in patients with GAN demonstrated a dose-dependent trend towards stabilization of visual acuity.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$0
Forward guidance
Taysha Gene Therapies expects to report clinical data for TSHA-120, engage with regulatory agencies for approval pathway of TSHA-120, report preliminary Phase 1/2 safety and biomarker data for TSHA-101, submit an IND application in the U.S. for TSHA-101, initiate a Phase 1/2 clinical trial in the U.S. for TSHA-101, initiate a Phase 1/2 clinical trial for TSHA-118, submit IND/CTA filing for TSHA-102, initiate Phase 1/2 clinical trial for TSHA-102, report clinical data for TSHA-102, submit IND/CTA filing for TSHA-104, initiate Phase 1/2 trial for TSHA-104.
Tailwinds
- Report clinical data for TSHA-120 from the high dose cohort of 3.5x10^14 total vg in second half of 2021
- Engage with key regulatory agencies to discuss the approval pathway and provide a regulatory update by year-end 2021
- Report preliminary Phase 1/2 safety and biomarker data (Queen’s University trial) in second half of 2021
- Submit an Investigational New Drug (IND) application in the U.S. in second half of 2021
- Initiate Phase 1/2 clinical trial in the U.S. in second half of 2021
Headwinds
- No specific negative guidance was provided in the earnings report.
- Risks regarding the business are described in detail in the company's SEC filings.
- Forward-looking statements are subject to risks and uncertainties.
- The impacts of the COVID-19 pandemic may amplify risks.
- The company disclaims any obligation to update forward-looking statements except as required by law.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro